Advertisement
UK markets close in 58 minutes

  • FTSE 100

    8,050.05
    +5.24 (+0.07%)
     

  • FTSE 250

    19,744.84
    -54.88 (-0.28%)
     

  • AIM

    754.81
    -0.06 (-0.01%)
     

  • GBP/EUR

    1.1629
    +0.0001 (+0.01%)
     

  • GBP/USD

    1.2441
    -0.0011 (-0.09%)
     

  • Bitcoin GBP

    52,470.59
    -1,297.75 (-2.41%)
     

  • CMC Crypto 200

    1,426.65
    +2.55 (+0.18%)
     

  • S&P 500

    5,078.92
    +8.37 (+0.17%)
     

  • DOW

    38,468.84
    -34.85 (-0.09%)
     

  • CRUDE OIL

    82.93
    -0.43 (-0.52%)
     

  • GOLD FUTURES

    2,334.70
    -7.40 (-0.32%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,113.52
    -24.13 (-0.13%)
     

  • CAC 40

    8,102.85
    -2.93 (-0.04%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

Zacks Equity Research
·2-min read

Aclaris Therapeutics (ACRS) shares ended the last trading session 5.5% higher at $15.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 23% gain over the past four weeks.

The company is riding on strong recommendations from analysts which suggests that the stock can gain more than double this year.

This specialty pharmaceutical company is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of -5.9%. Revenues are expected to be $1.59 million, down 12.4% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

ADVERTISEMENT

For Aclaris, the consensus EPS estimate for the quarter has been revised 2.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ACRS going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Aclaris is part of the Zacks Medical - Drugs industry. KemPharma (KMPH), another stock in the same industry, closed the last trading session 1.4% higher at $4.29. KMPH has returned -17.2% in the past month.

KemPharma's consensus EPS estimate for the upcoming report has changed -3.7% over the past month to -$0.14. Compared to the company's year-ago EPS, this represents a change of +65%. KemPharma currently boasts a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research